Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer

Fig. 3

In vivo [89Zr]Zr-cetuximab PET imaging tumor uptake after Src inhibition. Mice bearing tumors were treated with dasatinib or vehicle for 5 days before undergoing [89Zr]Zr-cetuximab PET imaging on day 7 (a). Representative maximum intensity projections (MIPs) of control (left) and dasatinib-treated (right) mice demonstrate higher uptake of [89Zr]Zr-cetuximab in treated MDA-MB-231 tumor cohorts (b, c). MIPs demonstrate higher uptake of [89Zr]Zr-cetuximab in treated MDA-MB-468 (right) vs. control (left) tumors at 48 h p.i. d and e demonstrate higher uptake of the tracer in treated groups compared to control. L = liver. Tumors are identified by a white circle

Back to article page